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Abstract
Background: Multiple sclerosis (MS) preferentially affects females at childbearing age. For this reason patients and treating
physicians were frequently confronted with questions concerning family planning, pregnancy and birth.
Objective: The aim of this study was to evaluate the expertise about pregnancy related topics in multiple sclerosis of
neurologists in private practice.
Methods: We developed a survey with 16 multiple choice questions about pregnancy related topics and sent it to
neurologists in private practice in Berlin, Germany.
Results: 56 completed questionnaires were sent back. 54% of all questions were answered correctly, 21% of the questions
were answered with ‘‘I don’t know’’. Correct answers were more often given by physicians who treat more than 400 MS
patients per year (p = 0.001). Further positive associations were found for assumed relevance of the topic (p = 0.002) and the
degree of counseling (p,0.001).
Conclusion: To provide a comprehensive counseling, MS patients with desire for children should be counseled by
physicians with a lot of experience in MS treatment.
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Introduction
Multiple sclerosis (MS) is a chronic autoimmune disease of the
central nervous system which particularly affects young women.
The male to female ratio ranges between 1:2–3 [1,2] and, while
incidence seems to increase in general [3,4], it seems to increase
even stronger in women [5]. First symptoms typically arise
between the third and fifth decade of life which overlaps with the
period of reproduction and family planning. Assuming a
prevalence in Europe of 70–80/100.000 during the third and
fourth decade [1], there are estimated to be 250.000 female MS
patients of fertile age in Europe. Hence, there is a great need of
patients for counseling about inheritance risk, sexual dysfunctions,
influence of MS on a pregnancy, birth and lactation, but also vice
versa about the effect of pregnancy on the MS course.
In the past, especially during the first half of 20th century,
female patients were often discouraged from becoming mother as
pregnancy was considered to be a risk in MS [6]. Although some
studies may suggest that MS increases the risk of adverse
pregnancy outcomes [7,8], the majority of studies could show
that risk of complications during pregnancy and birth outcome is
the same as in healthy women [9,10]. Many patients in our
outpatient department and in MS internet forums report that they
received the advice to deliver by caesarean section although
current studies show that it is not necessarily preferable to vaginal
delivery in MS patients [11,12]. Patients report to be frequently
advised against peridural anesthesia, although it is well document-
ed that peridural anaesthesia does not increase post partum relapse
rate and can be used in MS patients too [13]. The problem of
sexual dysfunction seems to be often underestimated as either
patients do not report these symptoms or physicians do not
routinely ask for them [14]. Briefly summarized, increasing data
regarding MS and pregnancy has become available in the
literature during the last years [15]. However, it is not known to
what extent these findings are transferred into today’s clinical
routine.
The uncertainties among patients and attending physicians also
apply to handling of MS pharmacotherapy. Within the last years
pregnancy registries could show that exposure to interferon beta
(IFN-b) and glatiramer acetate (GA) during conception and even
during pregnancy seems to be relatively safe [16,17]. However, it
is commonly agreed to discontinue IFN- b or GA treatment when
pregnancy is detected. Limited data concerning pregnancy is
available for the monoclonal antibody natalizumab and the
sphingosine receptor modulator fingolimod [18,19]. Mitoxantrone
is known for teratogenic effects, and its withdrawal is recom-
mended in female as well as in male patients at least six months
before pregnancy. Until now, there are no reliable data whether it
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is favorable to start immunomodulatory therapy (IMT) directly
after delivery instead of nursing or to postpone IMT in favor of
breastfeeding [20,21].
Taken together, MS patients that plan to conceive or are
already pregnant have currently unmet needs in terms of
guidance. As obstetricians are usually not experienced in MS
counseling and, vice versa, neurologists have only little knowledge
regarding obstetrics, pregnant MS patients may have difficulties to
get competent advice.
This study surveys neurologists as main source of information
for pregnant MS patients regarding delivery, course of the disease
and medication during pregnancy, child birth and lactation.
Methods
Prior to conducting our study we approached the institutional
review board of the Charite´ – Universita¨tsmedizin Berlin and
received approval for waiver of ethics committee vote.
We collected demographic and general data of the participants
(e.g. age, sex, year of completing residency and number of treated
MS patients). In Germany it is possible to pass board certification
only in neurology or in both neurology and psychiatry; therefore
we also asked for the individual specialization.
After a brought review of literature, we created a questionnaire
containing 16 multiple choice questions about pregnancy related
topics in MS. The questions were chosen among the issues that
were brought up most often by patients in our outpatient
department and that are topic of discussion in current literature
[15]. These questions were designed as multiple choice items with
single correct answer and ‘‘I don’t know’’ option; the language of
the questionnaire was German. The questionnaire is available as
supplement.
To evaluate the comprehensibility and time needed to complete
the questionnaire, questions and possible answers of the survey
were at first discussed and reviewed by neurologists and
obstetricians not participating in the study. Approximately 15
minutes were needed to fill in the questionnaire.
For further analysis, the 16 questions were assigned to one of
three categories.
1.) family planning before conception
2.) pregnancy and delivery
3.) period after delivery.
Category 1 contains questions 1–5, 15 and 16 which deal with
inheritance risk, frequency of sexual dysfunction, assisted repro-
duction technique, handling of immunomodulatory therapy
during time of contemplating pregnancy, and influence of
pregnancy on the long term course of MS.
Questions 6–11 address relapse rates during pregnancy,
pregnancy associated complications, treatment of relapses during
Table 1. Demographic characteristics.
Gender male 33 (59%)
female 23 (41%)
Age ,50 years 24 (43%)
$50 years 30 (54%)
not specified 2 (3%)
Board certification neurology 24 (43%)
neurology & psychiatry 32 (57%)
Period of board certification ,15 years 24 (43%)
$15 years 31 (55%)
not specified 1 (2%)
Private practice ,10 years 29 (52%)
$10 years 26 (46%)
not specified 1 (2%)
Treated MS patients per quarter ,10 21 (37%)
10–100 24 (43%)
.100 11 (20%)
Counseling of female patients concerning pregnancy related topics extensively 23 (41%)
to a certain degree 28 (50%)
not at all 5 (9%)
Counseling of male patients concerning pregnancy related topics extensively 14 (25%)
to a certain degree 35 (62%)
not at all 7 (13%)
Relevance of pregnancy aspects in MS very relevant 18 (32%)
moderately relevant 25 (45%)
little relevant 9 (16%)
not relevant 3 (5%)
not specified 1 (2%)
doi:10.1371/journal.pone.0099106.t001
Pregnancy in MS
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pregnancy, assisted delivery, peridural anaesthesia, and birth
outcome in MS patients; they are summed up in category 2.
Category 3 encloses the questions 12–14 which deal with relapse
rates after delivery, breast feeding, and immunomodulatory
therapy during lactation.
The questionnaire was mailed to all neurologists in outpatient
care in Berlin, registered at the Association of Statutory Health
Insurance Physicians (Kassena¨rztliche Vereinigung). Physicians
that treat mainly psychiatric patients (n = 101) were excluded from
the study. One month later a reminder was sent. Participants
received an expense allowance to the amount of 30 Euro.
Anonymity was assured by using two envelopes: informed consent,
accounting documents and the first envelope containing the
completed questionnaire were placed inside a second envelope. In
our institution the first envelope was stored separately from the
other documents; therefore a personal allocation to specific
persons was not possible.
Statistical analysis was performed by using SPSS Statistics
version 19. To compare percentages, Kruskal-Wallis-test and
Mann-Whitney-U-test were used for independent samples.
Wilcoxon signed rank-test was used to compare related samples.
Our study was an exploratory analysis, no power calculation had
previously been performed, and not more than three groups were
compared. Therefore no correction for multiple comparisons was
performed.
Results
Demographic Characteristics
Out of 248 neurologists, 56 sent back the completed question-
naire (response rate 23%). Mean age of respondents (6SD) was 52
(68.8) years. They passed board certification as a specialist in
neurology on average 17 (68.8) years ago and were in private
practice for 11 (69.2) years on average. 21 (37%) treat less than
10 MS patients per quarter, 24 (43%) attend 10–100 patients and
11 (20%) treat more than 100 MS patients per quarter. A
summary of demographic data is presented in Table 1.
Survey Results
About half (54%) of all questions were answered correctly.
Among those who indicated to counsel MS patients about
pregnancy related topics extensively or to a certain degree, the
rate of correct answers was 59%.
The question which was most frequently answered correctly
refers to MS relapse rate during pregnancy. 47 (84%) of the
participants knew that relapse rate decreases during the course of
pregnancy [13]. 42 (75%) were aware that the rate of pregnancy
related complications in MS patients is the same as in healthy
women. With 28 (50%) wrong answers the question about
frequency of sexual dysfunctions in MS patients was the question
most often answered incorrectly. Topics in which most of the
participants were aware of their lack of knowledge refer to assisted
delivery and artificial fertilization. 52% and 47%, respectively,
answered these questions with ‘‘I don’t know’’. Table 2 summa-
rizes the survey results.
After assigning the 16 questions to the three categories
mentioned above, we found the most correct answers (68%)
within category 2, which refers to the period of pregnancy and
questions about delivery. The questions about topics before the
beginning of pregnancy (category 1) were answered at least
correctly (55%) and mostly with ‘‘I don’t know’’ (18%).
Table 3 summarizes the results of the statistical analysis. We
compared the percentages of correct and ‘‘I don’t know’’ answers
for age, sex, board certification, duration in private practice,
number of treated MS patients, and the assumed relevance of the
topic pregnancy in MS. Moreover, we evaluated the degree of
counseling referring to time and content of counseling.
1. Influence of gender, age and board certification on survey results. Related
to gender, age and the kind of board certification there were no
differences in correct and ‘‘I don’t know’’ answers to all
questions and to the questions of the various groups.
2. Influence of period of board certification and duration in private practice on
survey results. If we compare neurologists who passed their exam
within the last 15 years to those who are specialized in
Table 2. Survey results.
correct incorrect I don’t know missing
Inheritance risk 31 (56%) 13 (23%) 9 (16%) 3 (5%)
Frequency of sexual dysfunctions 14 (25%) 28 (50%) 13 (23%) 1 (2%)
IMT before conception (female patients) 28 (50%) 19 (34%) 6 (11%) 3 (5%)
IMT before conception (male patients) 36 (64%) 8 (14%) 11 (20%) 1 (2%)
Escalation therapy before conception 14 (25%) 6 (11%) 11 (20%) 8 (14%)
Relapse rate during pregnancy 47 (84%) 3 (5%) 5 (9%) 1 (2%)
Complications during pregnancy 42 (75%) 7 (13%) 5 (9%) 2 (3%)
Relapse treatment during pregnancy 26 (46%) 18 (32%) 11 (20%) 1 (2%)
Assisted delivery 15 (27%) 11 (19%) 29 (52%) 1 (2%)
Peridural anaesthesie 41 (73%) 4 (7%) 10 (18%) 1 (2%)
Pregnancy outcome 35 (63%) 9 (16%) 10 (18%) 2 (3%)
Post partum relapse rate 37 (66%) 8 (14%) 8 (14%) 3 (5%)
Breast feeding 17 (31%) 27 (48%) 9 (16%) 3 (5%)
IMT post partum 33 (59%) 8 (14%) 7 (13%) 8 (14%)
Influence of pregnancies on longterm MS course 35 (63%) 3 (5%) 14 (25%) 4 (7%)
Assisted reproductive technique 12 (21%) 14 (25%) 26 (47%) 4 (7%)
IMT: immunomodulatory therapy.
doi:10.1371/journal.pone.0099106.t002
Pregnancy in MS
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neurology more than 15 years we found no significant
differences in correct and ‘‘I don’t know’’ answers to all
questions and to the questions of the various categories.
Moreover, there were no differences between physicians in
private practice over 10 years compared to neurologists less
than 10 years in private practice.
3. Association between number of treated MS patients and survey results.
The percentage of correct answers to all 16 questions
(p = 0.001) and to the questions of category 1 (p,0.001) was
significantly associated with the number of treated MS patients.
Moreover, the rate of questions answered with ‘‘I don’t know’’
decreases with rising numbers of attended patients for all
questions (p = 0.001) and for the questions of the various
categories (p,0.001; p = 0.001 and p = 0.01, respectively;
Figure 1).
4. Association between degree of counseling of female patients and survey
results. Significant correlations were found between the degree
of counseling and the number of correct answers to all 16
questions (p,0.001) and to questions of the three categories
(p,0.001, p = 0.001 and p = 0.004, respectively). Participants
that rarely advise patients about pregnancy topics significantly
more often answered ‘‘I don’t know’’ to all questions and to
questions of the single categories (p,0.001).
5. Association between degree of counseling of male patients and survey results.
The percentage of correct answers to all 16 questions (p,
0.001) and to the questions of the three categories (p,0.001,
p = 0.003 and p = 0.03) significantly correlated with the degree
of counseling. With rising degree of counseling the rate of
questions answered with ‘‘I don’t know’’ decreased for all
questions (p = 0.001) and for the questions of the three
categories (p = 0.001, p = 0.001 and p,0.001, respectively).
6. Influence of assumed relevance of pregnancy in MS on survey results.
Physicians that consider pregnancy in MS to be a relevant topic
in their practice more frequently answered correctly to all
questions (p = 0.002) and to questions of category 1 (p = 0.002)
and 2 (p = 0.006). Low assumed relevance is associated with
more ‘‘I don’t know’’ answers related to all of the 16 questions
(p = 0.001) and to questions of category 1 (p = 0.001), category
2 (p = 0.004) and category 3 (p = 0.014).
Discussion
The intention of the study was to investigate neurologists’
expertise in MS and pregnancy. Overall, respondents answered
about half of our questions correctly. Only seven out of 56 (13%)
participants indicated not to counsel male and/or female MS
patients about pregnancy and sending them to specialized
outpatient centers, to a gynecologist, general practitioner or other
neurologists. The remaining 49 (87%) physicians reported to
counsel MS patients at least to a certain extent. Erroneous
knowledge or knowledge gaps revealed by our survey are
particularly concerning as they might influence the treatment of
patients: for example, 27% of the participants would treat a MS
relapse with high dose methylprednisolone (MP) throughout
pregnancy. Although administration of MP is not strictly
contraindicated during pregnancy, one should be aware that
steroids are weak teratogens with higher risks for oral clefts (OR
3.35) [22], miscarriage (12 vs. 7%) [23], and preterm birth (27 vs.
11%) [23] after exposition during the first trimester [22–24].
Hence, a strict risk-benefit-assessment is required during the first
three months of pregnancy. In contrast, 10% are erroneously
convinced that MP is contraindicated throughout the entire
pregnancy, although during second and third trimester the use of
steroids does not seem to have adverse effects on the fetus [24].
Handling with IFN-b and GA in the context of pregnancy is
controversially discussed. According to IFN-b manufacturers’
information, starting of IFN-b therapy during pregnancy is
contraindicated. Likewise, it is common practice to discontinue
IFN-b or GA treatment when a pregnancy is detected. On the
other hand, the manufacturers indicate that in highly active MS
IFN-b discontinuation during pregnancy should be critically
weighted up against the risk of severe relapses and there are
several reports showing no detrimental effects when IFN-b and
GA were continued during pregnancy [25,26]. This view,
however, conflicts with Lu et al. [27], who in general recommend
discontinuation of DMT when a pregnancy is planned. This
recommendation is based on one single study where birth weight
and length were reduced on average by 114 g and 1.1 cm,
respectively [28]. However, unlike mitoxantrone, no precise
interval between withdrawal of IFN-b and begin of unprotected
sexual intercourse is defined in women planning to conceive. On
the contrary, some authors warn of leaving patients untreated
while waiting for conception [29].
Prevalence of sexual dysfunction is underestimated by many
physicians. 50% of respondents think that only 10 or 40% of MS
patients were affected by symptoms like reduced libido, erectile
dysfunction or disturbances of ejaculation. However, recent studies
showed that up to 70% of MS patients suffer from sexual
dysfunctions [30,31]. Moreover, 20% respectively 8% of respon-
dents erroneously think that a vaginal delivery mode or a peridural
anesthesia is responsible for higher relapse rate after delivery. That
is a cause of concern as thereby unnecessarily a primary caesarian
section may be recommended or patients unnecessarily avoid
peridural anesthesia. The questions most often answered with ‘‘I
don’t know’’ refer to assisted delivery and artificial fertilization
which reflects the necessity of close cooperation with obstetricians.
Overall, a fifth (21%) of all questions were answered with ‘‘I don’t
know’’.
Most knowledge gaps concern questions of category 1 dealing
with family planning before conception. This is a cause of concern
as incorrect advice at this time may have devastating consequences
such as abstaining from having children at all, or abortion or
congenital malformations due to certain medications. The
percentage of correct answers significantly increases when more
Figure 1. Percentage of correct and I don’t know-answers in
relation to the number of treated MS patients per quarter:
Kruskal-Wallis-test.
doi:10.1371/journal.pone.0099106.g001
Pregnancy in MS
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than 100 MS patients were treated per quarter (o 400 MS
patients per year).
Until now, the only study which investigated neurologists’
treatment regimes about gender specific topics in MS was
performed by Coyle et al [32]. In that study, which was reported
in 2004, up to 79% of respondents recommended discontinuing
IMT prior to planned conception, whereas in our study only 27%
counsel in this way. In our study 50% gave advice for
discontinuing IMT only after conception, compared to 20% in
the other study. These differences probably reflect the changes in
treatment strategies due to the increase of knowledge over the last
ten years. Further questions in the study by Coyle et al. [32] refer
to contraception, menstrual irregularities, hormone replacement
therapy, and breastfeeding. Other relevant topics such as
treatment of relapses during pregnancy and lactation, mode of
delivery, or risks of assisted reproductive technique were not
discussed. Another limitation of that study is that only female
neurologists were included. The surveyed cohort was less
homogenous than ours, as the interviewed physicians worked as
well in private practice as in academic and MS centers in the USA
and Canada. In our study only physicians in private practice in
Berlin were surveyed.
Our study has a number of limitations as well. As response rate
was only 23% a non-response bias cannot be ruled out. However,
previous questionnaire studies among physicians showed only few
differences between responders and non-responders [33–35]
suggesting that nonresponse bias may not be as crucial as in
surveys of the general population. Since only city-based physicians
in private practice were included it is impossible to estimate to
what degree our results are representative of other regions or
countries. Berlin is Germany’s largest city, and supposedly, the
overall offer for education is higher than in rural areas. Therefore
it cannot be ruled out that our survey performed in rural areas
might have resulted in a lower proportion of correct answers.
Although our findings are not applicable to rural areas, it is
possible that our results even overestimate physicians’ expertise in
general. Moreover, compared to neurologists in private practice,
hospital-based physicians and neurologists in other institutions
may differ in their expertise about pregnancy aspects in MS. To
address these issues, a survey of neurologists outside Berlin as well
as of physicians in academic centers and the comparison to
neurologists in private practice might be the objective of further
studies.
One fifth of the participants in our study do not consider
pregnancy to be a relevant topic in their practice. We assume that
those physicians who answered the questionnaire are in general
more interested in the topic than non-responders. Thus, it is
possible that expertise in general may be lower than determined in
our study. Likewise, we cannot rule out that respondents looked up
the relevant information which could also result in overestimation
of expertise.
To sum up, our results provide some insights into the state of
knowledge among neurologists in private practice in Berlin,
Germany. MS patients cannot take for granted to receive correct
advice concerning pregnancy related topics. Level of expertise rises
with the number of attended MS patients and assumed relevance
of the topic. Therefore MS patients should seek advice from
physicians attending a large number of MS patients. Many
uncertainties regarding assisted delivery and artificial fertilization
reveals the importance of close cooperation with attending
obstetricians.
Supporting Information
Questionnaire S1 Multiple sclerosis (MS), family planning and
pregnancy.
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